Surgery for the dysfunctional sacroiliac joint

New EVoluSIon Study Data Demonstrates Strong Support for the SImmetry® Sacroiliac Joint Fusion System

Retrieved on: 
Thursday, March 24, 2022
Patel v Mirza, Wurmlingen, LinkedIn, DO, Randomized controlled trial, Â, NASDAQ, Sacroiliac joint dysfunction, Veni, vidi, vici, Marketing, Diagnosis, Sacroiliac joint pain, Conservative management, VAS, Disability, SIJ, De Palma, Fusion, Canadian International Council, Standard of care, Sacroiliac joint, SI, Pain, Article 13, International Society, Twitter, INT, Surgery for the dysfunctional sacroiliac joint, ODI, NASS, North American Spine Society, MCID, GLOBE, Physician, Assessment, Solution, EVSI, Pathology, Patient, Medicine, Pharmaceutical industry, Medical imaging, Silviculture, Spine

Published in the February 2022 issue of the International Journal of Spine Surgery, Clinical Outcomes Following Minimally Invasive Sacroiliac Joint Fusion with Decortication: The EVoluSIon Clinical Study1, reports 12-month clinical outcomes following minimally invasive SIJ fusion using the SImmetry Sacroiliac Joint Fusion system to treat SIJ dysfunction.

Key Points: 
  • Published in the February 2022 issue of the International Journal of Spine Surgery, Clinical Outcomes Following Minimally Invasive Sacroiliac Joint Fusion with Decortication: The EVoluSIon Clinical Study1, reports 12-month clinical outcomes following minimally invasive SIJ fusion using the SImmetry Sacroiliac Joint Fusion system to treat SIJ dysfunction.
  • The SImmetry system is a minimally invasive SI joint fusion system that uses proven orthopedic principles, including joint decortication, bone grafting and fixation, to achieve true arthrodesis.
  • The ultimate goal of SI joint fusion is to stabilize the sacroiliac joint to relieve pain due to joint disruption and degeneration.
  • Two-Year Outcomes from a Randomized Controlled Trial of Minimally Invasive Sacroiliac Joint Fusion vs. Non-Surgical Management for Sacroiliac Joint Dysfunction.

SI-BONE, Inc. Announces Centene Establishes Positive Coverage for MIS SI Joint Fusion including the Triangular iFuse Implant System

Retrieved on: 
Wednesday, July 14, 2021
Musculoskeletal system, Anatomy, Pelvis, Branches of biology, Sacroiliitis, Sacroiliac joint dysfunction, Sacroiliac joint, Implant, Sacroiliac joint pain, Surgery for the dysfunctional sacroiliac joint

SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System.

Key Points: 
  • SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System.
  • This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.
  • The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.
  • In addition, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint.

Aurora Spine Corporation Announces Successful Launch of its Proprietary SiLO™ Posterior SI Joint Fusion System

Retrieved on: 
Monday, March 1, 2021
Anatomy, Musculoskeletal system, Torso, Pelvis, Sacroiliac joint, Sacrum, Sacroiliitis, Surgery for the dysfunctional sacroiliac joint

CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (Aurora Spine or the Company) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it has successfully launched its proprietary SiLOTM Posterior SI Joint Fusion System (SiLO), which was designed specifically for posterior sacroiliac joint fusion.

Key Points: 
  • CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (Aurora Spine or the Company) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it has successfully launched its proprietary SiLOTM Posterior SI Joint Fusion System (SiLO), which was designed specifically for posterior sacroiliac joint fusion.
  • Sacroiliac joint (SI Joint) fusion is a surgical procedure which fuses the iliac bone (pelvis) to the spine (sacrum) for stabilization.
  • The SiLOTM Posterior SI Joint Fusion System is a single graft Posterior SI-Fusion System made of human cortical bone and was developed to provide a simple, safe, and reproducible method of stabilizing and fusing the sacroiliac joint.
  • In a recent BONEZONE article titled SI Joint Fusion Market Has Rapid Growth Potential author Mike Evers wrote, Minimally invasive sacroiliac (SI) joint fusion is an increasingly common treatment for patients with low back pain due to SI joint dysfunction.

SI-BONE, Inc. Announces CIGNA Establishes Positive Coverage for MIS SI Joint Fusion using the iFuse Implant System

Retrieved on: 
Friday, December 13, 2019
Musculoskeletal system, Medical Subject Headings, Medical classification, Pelvis, Sacroiliitis, Sacroiliac joint dysfunction, Sacroiliac joint, Prosthetics, Implant, Sacroiliac joint pain, Surgery for the dysfunctional sacroiliac joint

CIGNAs decision to cover MIS SI joint fusion is a significant milestone in the continuing adoption of this important treatment for patients with SI joint dysfunction due to degenerative sacroiliitis or SI joint disruption.

Key Points: 
  • CIGNAs decision to cover MIS SI joint fusion is a significant milestone in the continuing adoption of this important treatment for patients with SI joint dysfunction due to degenerative sacroiliitis or SI joint disruption.
  • SI-BONE is a medical device company that pioneered the iFuse Implant System, a minimally invasive surgical system for fusion of the sacroiliac joint to treat sacroiliac joint dysfunction.
  • This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.
  • The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.

SI-BONE, Inc. Announces Wellmark Blue Cross Blue Shield Establishes Positive Coverage for MIS SI Joint Fusion Using iFuse

Retrieved on: 
Tuesday, September 3, 2019
Medical Subject Headings, Medical classification, Musculoskeletal system, Pelvis, Sacroiliitis, Sacroiliac joint dysfunction, Sacroiliac joint, Minimally invasive procedure, Sacroiliac joint pain, Surgery for the dysfunctional sacroiliac joint

In addition, effective September 1, 2019 Health New England has updated its MIS SI joint fusion medical policy to cover only the iFuse Implant System, when performed by a surgeon, for its approximately 200,000 members in Massachusetts.

Key Points: 
  • In addition, effective September 1, 2019 Health New England has updated its MIS SI joint fusion medical policy to cover only the iFuse Implant System, when performed by a surgeon, for its approximately 200,000 members in Massachusetts.
  • SI-BONE is a medical device company that pioneered the iFuse Implant System, a minimally invasive surgical system for fusion of the sacroiliac joint to treat sacroiliac joint dysfunction.
  • This body of evidence has enabled multiple government and private payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.
  • The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.